Schedule 13G ownership disclosure

Elicio Therapeutics, Inc.

Common Stock, par value $0.01 per share · CUSIP: 28657F103

Event date: 2025-01-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Knoll Capital Management, LLC

    Shares: 630,915.00 · Class: 5.2%

  • Fred Knoll

    Shares: 630,915.00 · Class: 5.2%

  • Gakasa Holdings, LLC

    Shares: 630,915.00 · Class: 5.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-009441
Form type
SCHEDULE 13G
Filer
Elicio Therapeutics, Inc.
CIK
CIK 1601485
Filed
Feb 05, 2025
Reporting period
Jan 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub